LABNIR FOR ORAL SUSPENSION

Indications

• Community-acquired pneumonia
• Acute exacerbations of chronic bronchitis
• Acute sinusitis
• Otitis media
• Skin and soft tissue infections

Dosage

Adults: The usual adult dose for cefdinir is 300 mg every 12 hours for 5 to 10 days, depending on the severity and type of infection. For certain indications, such as skin infections, 600 mg may be administered once

Mechanism of action

Cefdinir, like other beta-lactam antibiotics, exerts its bactericidal effect by inhibiting cell wall synthesis. It binds to penicillin-binding proteins (PBPs) within the bacterial cell wall, interfering with the transpeptidation process crucial for cell wall integrity. This action leads to cell lysis and death of susceptible bacteria. Additionally, cefdinir has shown affinity for PBPs 2 and 3 and may inhibit myeloperoxidase release extracellularly, although the significance of this is not fully understood.

Pharmacodynamics

Cefdinir is a bactericidal agent effective against a wide variety of bacterial pathogens. It demonstrates broad-spectrum activity, particularly against beta-lactamase-producing organisms, making it suitable for treating infections that are resistant to other cephalosporins. The drug's ability to penetrate bacterial cell walls and resist inactivation by certain enzymes enhances its therapeutic efficacy.

Pharmacokinetics

Cefdinir is well absorbed following oral administration, with peak plasma concentrations typically occurring within 2 to 4 hours. It has a bioavailability of approximately 25% to 30%. The drug is primarily eliminated via the kidneys, with renal clearance being a significant route of excretion. The half-life of cefdinir is approximately 1.7 hours, and adjustments may be necessary in patients with renal impairment.

Contra-indications

• Hypersensitivity to cefdinir, other cephalosporins, or any component of the formulation
• History of severe allergic reactions (e.g., anaphylaxis) to penicillins

Adverse effects

• Diarrhea
• Nausea
• Vomiting
• Rash
• Elevated liver enzymes
• Headache
• Dizziness

Interactions

• Antacids containing aluminum or magnesium may reduce absorption
• Iron supplements can decrease the absorption of cefdinir

Precautions

• Use with caution in patients with a history of gastrointestinal disease, particularly colitis
• Monitor for signs of anaphylaxis in patients with known allergies to beta-lactam antibiotics
• Renal impairment may require dose adjustment

Pregnancy

Cefdinir is categorized as pregnancy category B. Animal studies have not demonstrated a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

Breast-feeding

Cefdinir is excreted in breast milk in small amounts. Caution should be exercised when administered to nursing women.

Storage

Store at room temperature, away from moisture and heat. Keep the medication in its original container.

Formulations

• Capsules: 300 mg
• Oral suspension: 125 mg/5 mL, 250 mg/5 mL

Mechanism of action

Five-member thiazolidine rings that make up penicillins are replaced in cephalosporins by a six-member dihydrothiazine ring, conferring greater bactericidal activity. This 6-member ring enables cefdinir and other cephalosporins to resist inactivation by certain bacterial enzymes. With a mechanism similar to other beta-lactam antibiotics, the bactericidal activity of cefdinir is caused by the inhibition of cell wall synthesis via binding to penicillin-binding proteins (PBPs). Cefdinir, like other cephalosporins, penetrates the bacterial cell wall, combats inactivation by beta-lactamase enzymes, and inactivates penicillin-binding proteins. This interferes with the final step of transpeptidation in cell walls, eventually leading to cell lysis, which eventually leads to the death of bacteria that are susceptible to this drug. Cefdinir has shown affinity to penicillin protein binding proteins 2 and 3. It has also been shown to inhibit transpeptidase enzymes of various bacteria, which may play a role in its bactericidal action. One in vitro study suggests that cefdinir inhibits myeloperoxidase release extracellularly. The impact of this potential drug target in relation to its mechanism of action is unknown.

Pharmacodynamics

Cefdinir is a bactericidal agent that treats bacterial infections by interfering with cell wall synthesis. Cefdinir exerts broad-spectrum activity against a variety of gram-positive and gram-negative bacterial infections. It is effective against several beta-lactamase enzyme producing bacteria. As a result, many organisms that are resistant to other cephalosporins may be susceptible to cefdinir.